Additionally, the 36-month beta value for RCEL is 1.55. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for RCEL is 24.59M and currently, short sellers hold a 16.11% ratio of that float. The average trading volume of RCEL on June 13, 2025 was 250.05K shares.
RCEL) stock’s latest price update
AVITA Medical Inc (NASDAQ: RCEL)’s stock price has gone decline by -7.33 in comparison to its previous close of 5.80, however, the company has experienced a -12.03% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-06-03 that VALENCIA, Calif., June 03, 2025 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced that RECELLⓇ, including RECELLⓇ GO, has been recognized as the “Best New Technology Solution – Surgical” in the 2025 MedTech Breakthrough Awards.
RCEL’s Market Performance
AVITA Medical Inc (RCEL) has seen a -12.03% fall in stock performance for the week, with a -19.66% decline in the past month and a -37.13% plunge in the past quarter. The volatility ratio for the week is 2.43%, and the volatility levels for the past 30 days are at 3.70% for RCEL. The simple moving average for the last 20 days is -11.74% for RCEL’s stock, with a simple moving average of -44.89% for the last 200 days.
Analysts’ Opinion of RCEL
Many brokerage firms have already submitted their reports for RCEL stocks, with D. Boral Capital repeating the rating for RCEL by listing it as a “Buy.” The predicted price for RCEL in the upcoming period, according to D. Boral Capital is $25 based on the research report published on December 24, 2024 of the previous year 2024.
Cantor Fitzgerald gave a rating of “Overweight” to RCEL, setting the target price at $23 in the report published on June 27th of the previous year.
RCEL Trading at -29.84% from the 50-Day Moving Average
After a stumble in the market that brought RCEL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.04% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RCEL starting from McNamara Robert, who purchase 11,000 shares at the price of $8.30 back on Mar 06 ’25. After this action, McNamara Robert now owns 56,749 shares of AVITA Medical Inc, valued at $91,300 using the latest closing price.
McNamara Robert, the Director of AVITA Medical Inc, purchase 10,000 shares at $10.09 during a trade that took place back on Feb 20 ’25, which means that McNamara Robert is holding 45,749 shares at $100,900 based on the most recent closing price.
Stock Fundamentals for RCEL
Current profitability levels for the company are sitting at:
- -0.88 for the present operating margin
- 0.86 for the gross margin
The net margin for AVITA Medical Inc stands at -0.96. The total capital return value is set at -0.95. Equity return is now at value -407.50, with -68.34 for asset returns.
Based on AVITA Medical Inc (RCEL), the company’s capital structure generated 0.91 points at debt to capital in total, while cash flow to debt ratio is standing at -1.06. The debt to equity ratio resting at 10.22. The interest coverage ratio of the stock is -10.56.
Currently, EBITDA for the company is -55.34 million with net debt to EBITDA at -0.58. When we switch over and look at the enterprise to sales, we see a ratio of 2.73. The receivables turnover for the company is 5.37for trailing twelve months and the total asset turnover is 0.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.09.
Conclusion
In conclusion, AVITA Medical Inc (RCEL) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
